Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec;74(6):3559-3560.
doi: 10.1002/hep.32094. Epub 2021 Sep 16.

Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH

Affiliations
Comment

Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH

Karan Kumar et al. Hepatology. 2021 Dec.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, et al. Saroglitazar, a PPAR-α/γ agonist, for treatment of nonalcoholic fatty liver disease: a randomized controlled double-blind phase 2 trial. Hepatology 2021 Apr 2. https://doi.org/10.1002/hep.31843. [Epub ahead of print]
    1. Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP, et al. Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail. J Clin Transl Hepatol 2021;9:40-50.
    1. Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology 2015;61:153-160.
    1. Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 2013;33:1398-1405.
    1. Ma X, Liu S, Zhang J, Dong M, Wang Y, Wang M, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol 2020;20:10.

LinkOut - more resources